Journal of Clinical Pediatrics >
Genotypes and clinical phenotypes of Noonan syndrome in children with hypertrophic cardiomyopathy
Received date: 2021-08-30
Online published: 2023-02-16
Objective To retrospectively summarize the genetic variants and clinical characteristics of Noonan syndrome in children with hypertrophic cardiomyopathy (HCM). Methods A total of 123 children with HCM were enrolled in this study. Second generation sequencing and bioinformatic analysis of 96 genes associated with hypertrophic cardiomyopathy were performed in 123 probands. Eleven patients with diagnosed with Noonan syndrome, and their clinical data and echocardiographic findings were collected. Results The median age of diagnosis of HCM was 2 years and 7 months (5 months to 10 years), and the median age of diagnosis of Noonan syndrome was 6 years and 9 months (7 months to 16 years). 10 of 11 children had variants in RAF1 gene on chromosome 3, one had variant in PTPN11 gene on chromosome 12, and 7 had other novel variants. One of the patients with RAF1 was also found carrying variant in MYBPC3 which is associated with HCM. Nine out of 11 patients with HCM had typical facial features of Noonan syndrome. All 11 children had hypertrophic cardiomyopathy, 9 with obstructive hypertrophic cardiomyopathy, 2 with right ventricular outflow tract obstruction, and 7 with congenital heart disease. Conclusion RFA1 mutation is commonly seen in children with HCM in Noonan syndrome. Those patients carried with RFA1 mutation are more likely to have left ventricular outflow track obstruction and congenital heart diseases.
Xiaoli ZHU , Qianli YANG , Bo WANG , Shengjun TA , Xueli ZHAO , Jing LI , Shengquan CHENG , Liwen LIU . Genotypes and clinical phenotypes of Noonan syndrome in children with hypertrophic cardiomyopathy[J]. Journal of Clinical Pediatrics, 2023 , 41(2) : 125 -129 . DOI: 10.12372/jcp.2023.21e1258
[1] | 刘晓亮. Noonan综合征的诊治进展[J]. 临床儿科杂志, 2016, 34(1): 64-67. |
[2] | Roberts AE, Allanson JE, Tartaglia M, et al. Noonan syndrome[J]. Lancet, 2013, 381(9863): 333-342. |
[3] | 刘霞, 苏喆. Noonan综合征的诊断治疗进展[J]. 中华实用儿科临床杂志, 2014, 29(20): 1531-1533. |
[4] | Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J]. J Am Coll Cardiol, 2020, 76(25): 3022-3055. |
[5] | Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. J Am Soc Echocardiogr, 2015, 28(1): 1-39. e14. |
[6] | Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology[J]. Genet Med, 2015, 17(5): 405-424. |
[7] | 罗光月, 陆韦. Noonan综合征发病机制的研究进展[J]. 疑难病杂志, 2021, 20(10): 1077-1080. |
[8] | Romano AA, Allanson JE, Dahlgren J, et al. Noonan syndrome: clinical features, diagnosis, and management guidelines[J]. Pediatrics, 2010, 126(4): 746-759. |
[9] | Wu X, Yin J, Simpson J, et al. Increased BRAF heterodimerization is the common pathogenic mechanism for Noonan syndrome-associated RAF1 mutants[J]. Mol Cell Biol, 2012, 32(19): 3872-3890. |
[10] | 李辛, 王秀敏, 王剑, 等. Noonan综合征的临床实践指南[J]. 中华医学遗传学杂志, 2020, 37(3): 324-328. |
[11] | Lioncino M, Monda E, Verrillo F, et al. Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management[J]. Heart Fail Clin, 2021, 18(1): 19-29. |
[12] | Pierpont ME, Digilio MC. Cardiovascular disease in Noonan syndrome[J]. Curr Opin Pediatr, 2018, 30(5): 601-608. |
[13] | James D, April M, Bonnie A, et al. Outcomes in chlidren with Noonan syndrome and hypertrophic cardiomyopathy: a study from the pediatric cardiomyopathy registry[J]. Am Heart J, 2012, 164(3): 442-448. |
[14] | Prendiville TW, Gauvreau K, Tworog-Dube E, et al. Cardiovascular disease in Noonan syndrome[J]. Arch Dis Child, 2014, 99(7): 629-634. |
[15] | Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders[J]. Best Pract Res Clin Endocrinol Metab, 2011, 25(1): 161-179. |
[16] | Tafazoli A, Eshraghi P, Koleti ZK, et al. Noonan syndrome - a new survey[J]. Arch Med Sci, 2017, 13(1): 215-222. |
[17] | Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis[J]. Mol Syndromol, 2010, 1(1): 2-26. |
/
〈 |
|
〉 |